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ABSTRACT
Aims/Introduction: Glucagon-like peptide-1 (GLP-1) secreted from enteroendocrine L
cells is an incretin that potentiates insulin secretion and is already applied in therapies for
type 2 diabetes. However, detailed examination of L cells throughout the gastrointestinal
tract remains unclear, because of difficulties in purifying scattered L cells from other cells.
In the present study, we identified characteristics of L cells of the upper small intestine
(UI), the lower small intestine (LI) and the colon using glucagon-green fluorescent protein-
expressing mice that express GFP driven by the proglucagon promoter.
Materials and Methods: The localization and density of primary L cells were evalu-
ated by anti-green fluorescent protein antibody reactivity. GLP-1 content, messenger
ribonucleic acid (mRNA) expression levels and secretion in purified L cells were measured.
Results: The number of L cells significantly increased toward the colon. In contrast, the
GLP-1 content and secretion from L cells were higher in the UI than in the LI and colon.
L cells from the UI and LI expressed notably high mRNA levels of the transcription factor,
islet 1. The mRNA expression levels of peptide YY in L cells were higher in the LI than in
the UI and colon. The mRNA expression levels of gastric inhibitory polypeptide in L cells
from the UI were significantly higher compared with those from the LI and colon.
Conclusions: L cells show different numbers and characteristics throughout the gut,
and they express different mRNA levels of transcription factors and gastrointestinal hor-
mones. These results contribute to the therapeutic application of promoting GLP-1 release
from L cells for the treatment of type 2 diabetes.
INTRODUCTION
Gut–brain communication, the so-called enteric nervous sys-
tem, maintains complex homeostatic body states including
energy homeostasis1,2. Enteroendocrine cells (EECs) in the gas-
trointestinal (GI) tract secrete a large number of peptide hor-
mones that form a homologous family; these cells are
traditionally classiﬁed by immunocytochemistry into at least 10
different cell types3. More than 100 kinds of gut hormones
secreted from EECs have been identiﬁed; therefore, the gut is
recognized as the largest endocrine organ in the body4. How-
ever, analysis of EECs has been difﬁcult, because they comprise
<1% of all gut epithelial cells, and are not concentrated like
other endocrine organs.
Glucagon-like peptide-1 (GLP-1) is a 31-amino-acid polypep-
tide hormone produced in enteroendocrine L cells located
mainly in the distal part of the GI tract5. GLP-1 is one of the
major ‘incretins’ that potentiates a greater and more persistent
plasma insulin increase with an oral glucose load than it does
with intravenous glucose infusion6. GLP-1 also shows extrapan-
creatic effects in the cardiovascular system, GI tract and central
nervous system5–7. Therefore, GLP-1 has been targeted in clini-
cal applications in patients with type 2 diabetes by dipeptidyl
peptidase-4 inhibitors, which delay degradation of endogenous
GLP-1, and GLP-1 receptor mimetics6,7. Furthermore, the
increase in plasma GLP-1 levels is beneﬁcial in patients with
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type 2 diabetes. Another strategy for GLP-1 treatment stimu-
lates the release of GLP-1 from L cells8.
Different EECs are developed from close cell lineages, thus,
coexistence of several peptide hormones have been distin-
guished9. Proglucagon protein is produced from the progluca-
gon (Gcg) gene in L cells. Prohormone convertase (PC) 1/3
cleaves proglucagon into glicentin-speciﬁc peptide, GLP-1 and
GLP-2 in an L-cell-speciﬁc manner5,10. Furthermore, L cells
have been shown to co-express several related intestinal hor-
mones, such as peptide YY (PYY) and gastric inhibitory
polypeptide (GIP; also called glucose-dependent insulinotropic
polypeptide)11–13. Using mice lacking transcription factor genes,
such as paired-box domain transcription factor (Pax) 4, Pax6
and pancreatic duodenal homeobox 1 (Pdx1), several groups of
transcription factors have been suggested to have key roles in L
cells14–16.
L cells are located broadly from the upper intestine (UI) to
the colon; however, little is known about the L cell distribution
throughout the GI tract. Recently, transgenic mouse models
expressing green ﬂuorescent protein (GFP) variants under the
control of promoters of gut peptide precursors have been gen-
erated, enabling EEC analysis17,18. However, these modiﬁed
mice are altered through the use of transgenic engineering tech-
niques that represent the gain-of-function approach. In the pre-
sent study, we used previously established glucagon-GFP
knock-in (Gcg-GFP) mice that express GFP driven by the
native proglucagon promoter19, to analyze and purify L cells as
GFP-positive (GFP[+]) cells by ﬂow cytometry. The purpose of
the present study was to elucidate the differences between pri-
mary murine L cells in the UI, the lower small intestine (LI)
and the colon, with the aim of helping to establish a new thera-
peutic approach for increasing GLP-1 secretion from L cells in
patients with type 2 diabetes.
METHODS
Animals
Gcg-GFP heterozygous (Gcggfp/+) mice generated as reported
previously19 were backcrossed with the C57BL/6J strain for
more than 10 generations. The blood glucose levels, serum
insulin levels, plasma GLP-1 levels and L-cell population in the
Gcggfp/+ mice were not altered compared with those in wild-
type mice, as previously described (data not shown)19. We used
7–16-week-old heteromutant male mice to analyze GFP(+) and
GFP-negative (GFP[-]) cells as L cells and non-L cells, respec-
tively. The mice were housed in an air-controlled (25°C) room
with a dark–light cycle of 10:14 h. This study was carried out
in strict accordance with Directive 2010/63/EU for animal
experiments. Animal care and procedures were approved by
the Kyoto University Animal Care Committee. All efforts were
made to minimize the suffering of the animals.
Histological and quantitative analyses of the gut
Mice were killed by cervical dislocation and the GI tract was
quickly removed. The small intestine was divided into two
portions at the middle position, and the oral and rectal portions
were deﬁned as the UI and LI, respectively. Samples were ﬁxed
in Bouin’s solution and embedded in parafﬁn as previously
described20,21. In brief, parafﬁn sections were blocked for
15 min in 3% bovine serum albumin at room temperature, and
then incubated with a mouse monoclonal anti-GFP antibody
(sc-9996, 1:100; Santa Cruz Biotechnology Inc., Santa Cruz,
California, USA) as the primary antibody overnight at 4°C.
According to the manufacturer’s information, this antibody was
raised against amino acids 1–238 representing the full length
GFP of Aequorea victoria. The sections were then incubated
with a goat anti-mouse secondary antibody (A-11001, 1:200;
Life Technologies, Tokyo, Japan) for 1 h at room temperature.
Images were taken by a ﬂuorescent microscope with a BZ-
X700 system (KEYENCE Corporation, Osaka, Japan). A total
of 50 representative crypt–villus units from each slide were ran-
domly selected only when there was a complete longitudinal
section of a villus and its associated crypt. The length (lm) of
the crypt–villus units was measured from the tip to the base.
The number of GFP(+) cells was counted in the 50 representa-
tive crypt–villus units. The densities were expressed as the
number of GFP(+) cells per micrometer length of a crypt–villus
unit (cell/lm; n = 4–5).
Isolation and collection of L cells from mouse intestinal
epithelium
The isolation of L cells from mouse intestinal epithelium has
been described previously21. In brief, the intestine was injected
with Hank’s balanced salt solution containing 0.5 mg/mL colla-
genase P (Roche Diagnostics, Manheim, Germany), and incu-
bated at 37°C for 10 min in Krebs–Ringer bicarbonate buffer.
The digested intestinal epithelium was collected and rinsed.
Next, samples were ﬁltered with a cell strainer (352340, BD Fal-
con cell strainer; Becton, Dickinson and Company, Franklin
Lakes, New Jersey, USA). GFP(+) and GFP(-) cells from the
intestinal epithelium were analyzed and sorted as L cells and
non-L cells, respectively, using the BD FACS AriaTM ﬂow
cytometer (Becton Dickinson and Company). Sorted cells were
collected into the buffer.
Measurement of GLP-1 and GIP content in the sorted L cells
GFP(+) and GFP(-) cells (5,000 per segment) were sorted in
0.1 N HCl lysis buffer. The GLP-1 and GIP content in the cell
extracts were assayed using a total GLP-1 enzyme-linked
immunosorbent assay kit (Meso Scale Discovery, Gaithersburg,
Maryland, USA) and a total GIP enzyme-linked immunosor-
bent assay kit (Merck Millipore, Darmstadt, Germany), respec-
tively. Protein concentration was determined using the Bio-Rad
Protein Assay Kit (Bio-Rad Laboratories, Inc., Hercules, Califor-
nia, USA).
Assay of GLP-1 secretion by the sorted L cells
A total of 5,000 GFP(+) cells were sorted in 5.5 mmol/L glu-
cose Dulbecco’s modiﬁed Eagle’s medium from the UI and the
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LI of Gcggfp/+ mice after an overnight fast (16 h). After 15 min
of incubation with 25 mmol/L glucose Dulbecco’s modiﬁed
Eagle’s medium at 37°C, all samples were centrifuged for
3 min. The supernatants were collected and GLP-1 levels were
assayed using a total GLP-1 enzyme-linked immunosorbent
assay kit.
Ribonucleic acid extraction and quantitative reverse
transcription polymerase chain reaction
Total ribonucleic acid (RNA) was extracted with the PicoPure
RNA isolation kit (Applied Biosystems, Inc., Alameda, Califor-
nia, USA) from 2,000 sorted cells and treated with deoxyri-
bonuclease (Qiagen Inc., Valencia, California, USA).
Complement deoxyribonucleic acid was prepared by reverse
transcriptase (Invitrogen, Carlsbad, California, USA) with an
oligo(dT) primer (Invitrogen). The messenger RNA (mRNA)
levels were measured in a total volume of 20 lL by SYBR
Green-based reverse transcription polymerase chain reaction
using the StepOnePlusTM Real-Time PCR System (Applied
Biosystems Inc., Foster City, California, USA). Polymerase
chain reaction analysis was carried out with 0.2 lmol/L of the
primers listed in Table S1. Thermal cycling conditions were
denatured at 95°C for 10 min followed by 50 cycles of 95°C
for 15 s and 60°C for 1 min. Melting curve dynamics and the
absence of primer dimers were conﬁrmed. Peptidylprolyl iso-
merase A was used as the internal control for normalization.
All data are shown using the Dcycle threshold (DCT) method
(CT [internal control] - CT [target gene]).
Statistical analysis
The results are given as mean – standard error of the mean
(n = number of mice). Statistical signiﬁcance was determined
using paired and unpaired Student’s t-test and analysis of vari-
ance with the Games–Howell test. P < 0.05 was considered
statistically signiﬁcant.
RESULTS
Density and quality of L cells in Gcggfp/+ mice
Gcggfp/+ mice enabled the identiﬁcation of L cells and non-L
cells as GFP(+) cells and GFP(-) cells, respectively (Figure 1a).
L cells were observed in the UI, LI and colon of Gcggfp/+ mice.
The length of the crypt–villus units of the LI (319.0 –
17.5 lm), and the colon (194.3 – 5.7 lm) was signiﬁcantly
shorter than that of the UI (583.6 – 19.6 lm; Figure 1b). The
number of L cells per crypt–villus unit was larger in the LI
(0.46 – 0.02) and the colon (0.44 – 0.04) than that in the UI
(0.12 – 0.36; Figure 1c). The density of L cells in the length of
the crypt–villus was the highest in the colon (0.114 –
0.012 cells/lm), followed by the LI (0.073 – 0.004 cells/lm)
and then the UI (0.010 – 0.002 cells/lm; Figure 1d).
The GLP-1 content in the L cells from the UI
(1630 – 224 pg/mL/protein), LI (487 – 54 pg/mL/protein) and
colon (684 – 165 pg/mL/protein) was signiﬁcantly higher than
that in the non-L cells of each part (Figure 1e). Furthermore,
the L cells from the UI contained approximately threefold more
GLP-1 compared with the L cells from the LI and colon (Fig-
ure 1e). Because GLP-1 is processed from the proglucagon
gene5, GLP-1 expression was assessed by the expression levels
of Gcg mRNA. A set of primers for the Gcg mRNA was
designed to span an exon–intron junction from exon 3 to exon
4. Neither GLP-1 content nor Gcg mRNA was detected in non-
L cells of each part. The mRNA expression levels of Gcg were
signiﬁcantly higher in L cells than in non-L cells of all parts of
the GI tract (Figure 1f). The mRNA expression levels of Gcg in
L cells from the UI were 1.8-fold higher than those in cells
from the LI (Figure 1f). GLP-1 is produced in L cells through
cleavage of proglucagon by PC1/3. The mRNA expression
levels of PC1/3 were signiﬁcantly higher in L cells than those in
non-L cells in the UI, and tended to be higher in L cells than
those in non-L cells in the LI (Figure 1g). The expression levels
of PC1/3 mRNA were very low in L cells from the colon. PC2
mRNA was not detected in either L cells or non-L cells from
the UI, LI and colon (data not shown). GLP-1 secretion in
response to glucose stimulation was signiﬁcantly higher in the
L cells from the UI, compared with that in cells from the LI
(Figure 1h).
Expression levels of transcription factors in L cells
We measured the mRNA expression levels of representative
transcription factors in sorted L cells (Figure 2). These tran-
scription factors have been suggested to be expressed in L cells
and other EECs. The expression levels of islet 1 (Isl1) mRNA
were signiﬁcantly higher in L cells compared with those in
non-L cells from the UI and LI (Figure 2b). Furthermore, L
cells from the UI and LI showed signiﬁcantly higher Isl1
expression than L cells from the colon. L cells from the LI
showed signiﬁcantly higher expression of Pax6 mRNA than L
cells from the colon (Figure 2c). The expression levels of regu-
latory factor X 6 (Rfx6) mRNA in L cells from the UI were sig-
niﬁcantly higher than those in non-L cells from the UI
(Figure 2e). Finally, there were no differences in the mRNA
expression of Pdx1 and Pax4 between the L cells of each part
(Figure 2a,d).
Expression of other intestinal hormones in L cells
We next measured the content of another incretin peptide,
GIP, and the mRNA expression levels of other enteroendocrine
hormones in L cells (Figure 3). In the UI, the GIP content in L
cells was signiﬁcantly higher than that in non-L cells (Fig-
ure 3a). Figure 3a and b shows that expression levels of GIP
protein parallel mRNA expression levels of GIP in L cells. The
mRNA expression levels of GIP in L cells from the UI were
signiﬁcantly higher compared with those in cells from the LI
and colon (Figure 3b). The mRNA expression levels of PYY, se-
cretin and cholecystokinin (CCK) were signiﬁcantly higher in L
cells than those in non-L cells in all parts of the GI tract (Fig-
ure 3c–e). The mRNA expression of PYY in L cells from the
LI was higher than that in cells from the UI and colon
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(Figure 3c). The expression of secretin mRNA in the L cells
from the UI and LI was higher than that in cells from the
colon (Figure 3d). The expression levels of CCK mRNA in L
cells were the highest in the UI, second highest in the LI and
the lowest in the colon (Figure 3e). Somatostatin mRNA was
barely expressed in the L cells of each segment, similar to the
case of non-L cells (Figure 3f).
DISCUSSION
In the present study, Gcg-GFP mice expressing GFP under the
control of the native proglucagon promoter enabled us to
directly assess L cells, revealing quantitative and qualitative
differences between L cells in the UI, LI, and colon. The pre-
sent ﬁndings showed that the number of L cells increases from
the UI to the colon, and that they have different expression
patterns of transcription factors and hormones.
The classiﬁcations of EECs and hormones have historically
relied on granule morphology and immunochemical studies3,4.
The immunoreactivity technique has shown that L-cells contain
several hormones4,13. Although the speciﬁcity of antibodies has
always been discussed, L cells have been shown to exist broadly
in the GI tract and occur most often in the LI5. A recent report
using ﬂuorescently labeled L cells showed an increase in density

















































































































































































































































Figure 1 | The density and quality of L cells in the gastrointestinal (GI) tract of glucagon (Gcg)-green fluorescent protein (GFP) knock-in (Gcg-GFP)
heterozygous (Gcggfp/+) mice. (a) Immunohistochemical images of the upper small intestine (UI), lower small intestine (LI) and colon of Gcggfp/+
mice (bright field image and fluorescence image). (b) The length of the crypt–villus units in the UI, LI and colon was measured by
immunohistochemistry (n = 5). (c) The number of GFP-positive (+) cells per crypt–villus unit (n = 5). (d) The density of GFP(+) cells was normalized
against the length of the crypt–villus unit (n = 5). (e) Glucagon-like peptide-1 (GLP-1) content in GFP(+) cells and GFP(–) cells from the UI, LI and
colon (n = 5). (f, g) The messenger ribonucleic acid expression levels of Gcg and prohormone convertase (PC) 1/3 in GFP(+) and GFP(–) cells from
the UI, LI, and colon (n = 5). Expression levels were normalized against the internal control, peptidylprolyl isomerase A (PPIA). (h) GLP-1 secretion
from GFP(+) cells from the UI and LI (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. NS, not significant.
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localization and the number of L cells using anti-GFP antibody
reactivity matched the ﬁndings of previous studies showing an
increase in the number of L cells toward the colon5. Addition-
ally, the function of the GI tract has been evaluated by the sur-
face area, which differs in each part of the tract. Therefore, we
measured the density of L cells as L cells/length of the crypt–
villus unit to compensate for the different surface area of each
part. Our study showed that the highest density of L cells
throughout the GI was in the colon. In the present study, we
used only adult male mice to evaluate the characteristics and
distribution of L cells. The effect of aging and sex on the local-
ization and density of primary L cells is yet unknown.
We also characterized L cells from the UI, LI and colon. The
GLP-1 content and expression levels of Gcg mRNA were higher
in the UI compared with the LI and colon. Previous reports
have shown lower expression levels of Gcg mRNA in L cells
from the UI compared with the colon11,17. Conversely, recent
reports have shown that L cells in the UI exhibit GLP-1 secre-
tion12. This discrepancy might stem from the differences
between transgenic mice and our knock-in mice. Thus, these
data indicate that L cells exhibit differences not only in their
numbers throughout the GI tract, but also in terms of molecu-
lar characteristics.
L cells secrete GLP-1 into the circulation in response to various
nutrients and neuromodulators. Whether the early postprandial
GLP-1 secretion originates from a few L cells in the UI or from L
cells located further down the tract in the LI and colon is not
clear. It has been suggested that a neural signal from the UI
reaches L cells in the more distal intestine and colon22. The
present data showed that GFP(+) L cells from the UI had the
highest amount of GLP-1 content, the highest expression levels
of Gcg mRNA. Furthermore, an ex vivo GLP-1 secretion experi-
ment showed higher GLP-1 secretion from L cells in the UI.
Therefore, the small number of L cells in the UI might explain
the capacity to activate early postprandial secretion of GLP-1.
PC1/3 is an essential enzyme for producing GLP-1 from pro-
glucagon protein. Expression levels of PC1/3 mRNA were
increased in L cells of UI compared with those of LI, suggesting
that GLP-1 synthesis is increased in L cells of the UI. In con-
trast, PC1/3 mRNA expression levels were extremely low, but
GLP-1 protein levels were detectable in L cells of the colon. It
is unclear how much PC1/3 mRNA expression level in L cells
is required for PC1/3 enzymatic activity, but there would be a
possibility that PC1/3 enzymatic activity in L cells is differently
regulated depending on the distribution. Although we could
not measure the PC1/3 enzymatic activity in L cells, further
study is required to clarify the mechanism.
Studies using transcription factor-deﬁcient mice have indi-
rectly conﬁrmed the requirement of speciﬁc transcription fac-
tors in the development of the EEC lineage23–25. However,
little is known about the expression of transcription factors in





































































































































Figure 2 | Expression of transcription factors in L cells. (a–e) The messenger ribonucleic acid expression levels of transcription factors in green
fluorescent protein (GFP)-positive (GFP[+]) cells and GFP-negative (GFP[–]) cells from the upper small intestine (UI), lower small intestine (LI) and
colon (n = 5). Expression levels were normalized against the internal control, peptidylprolyl isomerase A (PPIA). *P < 0.05, **P < 0.01, ***P < 0.001.
Isl1, islet 1; NS, not significant; Pax4, paired box gene 4; Pax6, paired box gene 6; Pdx1, pancreatic duodenal homeobox 1; Rfx6, regulatory factor X 6.
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proglucagon gene in L cells15, our data showed that Pax6 was
expressed in L cells and non-L cells at the same level. We
could not detect any transcription factor speciﬁc to L cells,
even in L-cells from the UI, which contained the highest
amount of GLP-1 (Figure 2). Nevertheless, the present results
revealed that Isl1 showed signiﬁcantly higher expression in L
cells from the UI and LI. Isl1 is a LIM-homeodomain tran-
scription factor that promotes islet cell proliferation26. Addi-
tionally, mice with intestinal epithelial-speciﬁc deletion of Isl1
showed loss of GLP-1, GIP, CCK and somatostatin-expressing
cells, and impaired glucose homeostasis27. We found that Isl1
was expressed at higher levels in L cells from the UI and LI.
Isl1 might not only be involved in L cell development, but
also in GLP-1 synthesis; however, further experiments are
required to clarify the role of Isl1 in GLP-1 expression. In
Rfx6-deﬁcient mice, none of the endocrine cells, excluding
pancreatic polypeptide-expressing cells, were detected in the
islets of these mice28. Here, we conﬁrmed a notable mRNA
expression of Rfx6 and GIP in L cells from the UI. GIP is
one other incretin secreted from K cells located in the duode-
num and UI29. In our previous report21, we showed that Rfx6
plays critical roles in GIP expression, but not in GLP-1
expression. Another report has shown that L cells in the UI
are more similar to K cells in the UI than to L cells in the LI
and colon11. Considering our results and these reports, we
propose that Rfx6 induces GIP expression in L cells located in
the UI, but further study is required.
The developmental relationships between EECs that arise
from secretory precursors have been examined by genetically
engineered mice9,18,29. The ablation of secretin-producing cells
decreased the number of L cells and CCK-producing cells, sug-
gesting that these cells are developmentally related9. Tissue-
speciﬁc post-translational processing of proglucagon in L cells
produces GLP-1 and GLP-2. Elimination of the proglucagon
promoter resulted in reduction in GLP-1, PYY, CCK, secretin
and GIP18. These results suggest that EECs co-express several
kinds of functionally related hormones. Recent studies have
shown that different EECs have more hormones than originally
thought, and that the expression patterns of GI hormones
depend on their localization11. L cells from Gcg-GFP mice also
expressed several GI hormones: PYY, GIP, secretin and CCK.
We observed signiﬁcant differences in the expression patterns
of these GI hormones depending on their distribution. PYY has
also been identiﬁed for its role in regulating appetite and body-
weight30. We observed a signiﬁcant high expression of PYY in
L cells from the LI. This result is consistent with that by Svend-
sen et al.12, who showed that PYY is secreted from L cells in
the distal part of the intestine. CCK-GFP mice have shown that
CCK-producing cells in the duodenum express Gcg, PYY, GIP
and secretin31. Using speciﬁc genetically engineered Gcg-GFP
mice, we conﬁrmed that L cells from the UI also express signif-
icantly high CCK and secretin mRNA.
In clinical practice, GLP-1 secretion in patients with type 2



































































































































































Figure 3 | Expression of enteroendocrine hormones in L cells. (a) Gastric inhibitory polypeptide (GIP) content in GFP-positive (GFP[+]) cells and
GFP-negative (GFP[–]) cells from the upper small intestine (UI), lower small intestine (LI), and colon (n = 5). (b–f) GIP, peptide YY (PYY), secretin,
cholecystokinin (CCK) and somatostatin messenger ribonucleic acid levels in GFP(+) and GFP(–) cells from the UI, LI, and colon (n = 5). Expression
levels were normalized against the internal control, peptidylprolyl isomerase A (PPIA). *P < 0.05, **P < 0.01, ***P < 0.001. NS, not significant.
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preserved32. Therefore, GLP-1-based therapies have been devel-
oped for patients with type 2 diabetes5–7. Recent investigations
have shown that the increased plasma GLP-1 concentration in
patients with type 2 diabetes who underwent a gastric bypass or
sleeve gastrectomy surgery normalized their blood glucose
levels7,33. It has been reported that the possible mechanisms are
that these surgeries lead to gut hypertrophy and an increase in
the number of L cells in the LI, resulting in increased plasma
GLP-1 levels34,35. However, these kinds of surgery are greatly
invasive and expensive. As we showed that L cells from the UI
contain the highest amount of GLP-1, a strategy for stimulating
GLP-1 exocytosis might be efﬁcient for L cells in the UI. Addi-
tionally, increasing the number of L cells in the UI by promoting
differentiation might enable patients to signiﬁcantly elevate their
plasma GLP-1 levels. The present results suggest the therapeutic
potential of promoting GLP-1 release from L cells for the treat-
ment of type 2 diabetes; however, further research is required.
In conclusion, using Gcg-GFP mice as an L cell reporter
model, we clearly showed that L cells exhibit different numbers
and characteristics depending on their distribution in the gut. L
cells also express different levels of gut hormones and transcrip-
tion factors’ mRNA.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article:
Table S1 | Oligonucleotide primers used for the quantitative reverse transcription polymerase chain reaction analysis.
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